front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |review |
1. Smith WL, Langen BR. Why there are two cyclooxygenase isoenzymes. J Clin Invest 2001;107: 1491-95. 2. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107(6A):11-16. 3. Simon LS. Are the biologic and clinical erfects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs? Curr Opin Rheumatol 2000;12:163-70. 4. Wallace, J.L. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal antiinflammatory drugs (NSAIDs). Am. J. Med., 107 11S-16S, 1999. 5. McCormack K. Novel aspects of pain management, Opioids and beyond. J. Sawynok, A. Cowan (eds.). New York: John Wiley & Sons Inc. 1997. |